TRADES
Latest Trades
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKK 20 Apr 2023 Buy ROKU ROKU INC 53,381 0.0416
ARKK 20 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 12,749 0.0051
ARKK 20 Apr 2023 Sell EXAS EXACT SCIENCES CORP 4,556 0.0041
ARKK 20 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 61,773 0.0010
ARKW 20 Apr 2023 Sell DKNG DRAFTKINGS INC 286,817 0.4973
ARKW 20 Apr 2023 Buy TSLA TESLA INC 36,213 0.4827
ARKW 20 Apr 2023 Buy ROKU ROKU INC 8,446 0.0402
ARKG 19 Apr 2023 Buy SLGC SOMALOGIC INC 333,347 0.0508
ARKG 19 Apr 2023 Sell EXAS EXACT SCIENCES CORP 11,553 0.0389
ARKG 19 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 11,048 0.0174
ARKG 19 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 157,863 0.0104
ARKK 19 Apr 2023 Sell EXAS EXACT SCIENCES CORP 119,861 0.1048
ARKK 19 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 37,291 0.0153
ARKK 19 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 603,036 0.0104
ARKQ 19 Apr 2023 Sell NIU NIU TECHNOLOGIES 100 0.0000
ARKF 18 Apr 2023 Buy RBLX ROBLOX CORP 21,035 0.1039
ARKF 18 Apr 2023 Sell MELI MERCADOLIBRE INC 621 0.1003
ARKG 18 Apr 2023 Buy SLGC SOMALOGIC INC 396,872 0.0611
ARKG 18 Apr 2023 Sell EXAS EXACT SCIENCES CORP 11,308 0.0380
ARKG 18 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 9,514 0.0150
ARKG 18 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 120,357 0.0076
ARKK 18 Apr 2023 Sell EXAS EXACT SCIENCES CORP 123,703 0.1083
ARKK 18 Apr 2023 Buy RBLX ROBLOX CORP 190,263 0.1018
ARKK 18 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 31,660 0.0130
ARKK 18 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 482,233 0.0079
ARKF 17 Apr 2023 Buy RBLX ROBLOX CORP 40,378 0.1990
ARKF 17 Apr 2023 Sell MELI MERCADOLIBRE INC 1,225 0.1952
ARKG 17 Apr 2023 Buy SLGC SOMALOGIC INC 70,972 0.0112
ARKG 17 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 150,177 0.0098
ARKK 17 Apr 2023 Buy RBLX ROBLOX CORP 382,056 0.2069
ARKK 17 Apr 2023 Sell EXAS EXACT SCIENCES CORP 136,604 0.1216
ARKK 17 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 481,320 0.0082
ARKQ 17 Apr 2023 Sell NIU NIU TECHNOLOGIES 100 0.0000
ARKW 17 Apr 2023 Sell MELI MERCADOLIBRE INC 1,927 0.2011
ARKW 17 Apr 2023 Buy RBLX ROBLOX CORP 62,046 0.2002
ARKG 14 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 213,511 0.0140
ARKG 14 Apr 2023 Buy SLGC SOMALOGIC INC 76,360 0.0118
ARKG 14 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 1,873 0.0030
ARKK 14 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 815,954 0.0141
ARKK 14 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 6,869 0.0029
ARKG 13 Apr 2023 Sell TXG 10X GENOMICS INC 8,280 0.0239
ARKG 13 Apr 2023 Sell EXAS EXACT SCIENCES CORP 4,653 0.0164
ARKG 13 Apr 2023 Buy SLGC SOMALOGIC INC 56,816 0.0092
ARKG 13 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 56,820 0.0039
ARKK 13 Apr 2023 Sell EXAS EXACT SCIENCES CORP 25,891 0.0237
ARKK 13 Apr 2023 Sell TXG 10X GENOMICS INC 21,426 0.0161
ARKK 13 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 180,576 0.0032
ARKG 12 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 13,764 0.0318
ARKG 12 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 331,951 0.0221
ARKG 12 Apr 2023 Buy TDOC TELADOC INC 14,208 0.0188
ARKG 12 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 24,019 0.0170
ARKG 12 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 4,042 0.0062
ARKG 12 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 5,144 0.0024
ARKG 12 Apr 2023 Sell EXAS EXACT SCIENCES CORP 342 0.0012
ARKG 12 Apr 2023 Sell TXG 10X GENOMICS INC 417 0.0012
ARKK 12 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 42,728 0.0257
ARKK 12 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,441,455 0.0251
ARKK 12 Apr 2023 Buy TDOC TELADOC INC 58,253 0.0201
ARKK 12 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 98,662 0.0183
ARKK 12 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 15,523 0.0062
ARKK 12 Apr 2023 Sell TXG 10X GENOMICS INC 2,495 0.0018
ARKK 12 Apr 2023 Sell EXAS EXACT SCIENCES CORP 1,481 0.0014
ARKQ 12 Apr 2023 Buy JOBY JOBY AVIATION INC 55,446 0.0259
ARKG 11 Apr 2023 Sell EXAS EXACT SCIENCES CORP 8,669 0.0303
ARKG 11 Apr 2023 Sell TXG 10X GENOMICS INC 2,124 0.0059
ARKG 11 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 6,576 0.0047
ARKG 11 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 979 0.0023
ARKG 11 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 699 0.0003
ARKK 11 Apr 2023 Sell EXAS EXACT SCIENCES CORP 28,497 0.0257
ARKK 11 Apr 2023 Buy U UNITY SOFTWARE INC 48,949 0.0203
ARKK 11 Apr 2023 Sell DKNG DRAFTKINGS INC 53,650 0.0134
ARKK 11 Apr 2023 Sell TXG 10X GENOMICS INC 7,663 0.0055
ARKK 11 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 21,802 0.0040
ARKK 11 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 4,262 0.0026
ARKQ 11 Apr 2023 Sell KMTUY KOMATSU LTD 29,447 0.0772
ARKQ 11 Apr 2023 Buy U UNITY SOFTWARE INC 4,618 0.0157
ARKW 11 Apr 2023 Buy U UNITY SOFTWARE INC 10,036 0.0247
ARKW 11 Apr 2023 Sell DKNG DRAFTKINGS INC 9,718 0.0144
ARKX 11 Apr 2023 Buy U UNITY SOFTWARE INC 1,416 0.0159
ARKG 10 Apr 2023 Sell TXG 10X GENOMICS INC 7,631 0.0208
ARKG 10 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 7,785 0.0182
ARKG 10 Apr 2023 Buy NTLA INTELLIA THERAPEUTICS INC 4,276 0.0078
ARKG 10 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 10,088 0.0071
ARKG 10 Apr 2023 Sell EXAS EXACT SCIENCES CORP 1,237 0.0043
ARKG 10 Apr 2023 Buy TDOC TELADOC INC 2,108 0.0028
ARKG 10 Apr 2023 Buy SLGC SOMALOGIC INC 19,335 0.0027
ARKG 10 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 4,486 0.0020
ARKG 10 Apr 2023 Buy PRME PRIME MEDICINE INC 386 0.0002
ARKG 10 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 96 0.0001
ARKG 10 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 548 0.0000
ARKK 10 Apr 2023 Sell DKNG DRAFTKINGS INC 295,139 0.0727
ARKK 10 Apr 2023 Buy U UNITY SOFTWARE INC 154,387 0.0633
ARKK 10 Apr 2023 Sell TXG 10X GENOMICS INC 30,354 0.0214
ARKK 10 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 29,245 0.0177
ARKK 10 Apr 2023 Buy NTLA INTELLIA THERAPEUTICS INC 19,827 0.0094
ARKK 10 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 38,475 0.0070
ARKK 10 Apr 2023 Sell EXAS EXACT SCIENCES CORP 3,994 0.0036
ARKK 10 Apr 2023 Buy TDOC TELADOC INC 6,235 0.0021
ARKK 10 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 431 0.0002
ARKK 10 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,917 0.0000
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.